Clinical trials: Hematologic Diseases
Solid Tumors, Hematologic Malignancies
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors.
- Conditions
- Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome
- Trial name
- NCT00741234
- Testing
- SB939, Azacitidine
- Where
- 5 sites in United States, Singapore
- Volunteers
- 85 people
- Sponsor
- S*BIO
Castrate Resistant Prostate Cancer, NUT Carcinoma
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
- Conditions
- Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
- Trial name
- NCT05488548
- Testing
- EP31670
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- Epigenetix, Inc.
Advanced Solid Tumors or Hematologic Malignancies
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
APG-1387 is a potent, bivalent small-molecule Inhibitor of Apoptosis Protein (IAP) antagonist. APG-1387 has shown strong dose- and schedule-dependent antitumor activities in multiple human cancer xenograft models, APG-1387 also…
- Trial name
- NCT03386526
- Testing
- APG-1387 for Injection
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Hemophilia B
Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B
To assess efficacy and safety of BeneFix® for prophylaxis in "Short-term" therapy and on demand therapy for all bleeding episodes of subjects with hemophilia B.
- Trial name
- NCT00581126
- Testing
- Recombinant Factor IX Coagulation
- Volunteers
- 14 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Myelodysplastic Syndrome
Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)
The purpose of this study is to determine if AR-67 is effective in the treatment for patients with MDS.
- Trial name
- NCT00956787
- Testing
- AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Arno Therapeutics
Chronic Lymphocytic Leukemia
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
This is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL).
- Trial name
- ASSURE (NCT04008706)
- Testing
- Acalabrutinib
- Where
- 108 sites in United States, Australia and 15 more
- Volunteers
- 552 people
- Sponsor
- AstraZeneca
Lung Cancer, Solid Tumor
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies.
- Conditions
- Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer
- Trial name
- NCT02393248
- Testing
- Pemigatinib, Gemcitabine, Pembrolizumab
- Where
- 20 sites in United States, Denmark
- Volunteers
- 201 people
- Sponsor
- Incyte Corporation
Multiple Myeloma
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
- Trial name
- NCT03448978
- Testing
- Descartes-08, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Cartesian Therapeutics
Relapsed or Refractory Multiple Myeloma
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or…
- Trial name
- MajesTEC-9 (NCT05572515)
- Testing
- Teclistamab, Pomalidomide, Bortezomib
- Where
- 211 sites in United States, Australia and 22 more
- Volunteers
- 614 people
- Sponsor
- Janssen Research & Development, LLC
Hemophilia A
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A
This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with congenital hemophilia A.
- Trial name
- NCT01434511
- Testing
- OBI-1
- Where
- 3 sites in United States, South Africa and 1 more
- Volunteers
- 1 people
- Sponsor
- Baxalta now part of Shire
Primary Myelofibrosis, Myelodysplastic Syndromes
Connect® Myeloid Disease Registry
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical…
- Conditions
- Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
- Trial name
- NCT01688011
- Testing
- Luspatercept
- Where
- 158 sites in United States, Puerto Rico
- Volunteers
- 2,013 people
- Sponsor
- Celgene
Hemophilia A
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
The main aim of this study is to check for long-term side effects from ADYNOVI/ADYNOVATE prophylaxis in participants with haemophilia A when used under standard clinical practice in the real-world clinical setting.
- Trial name
- NCT04158934
- Testing
- ADYNOVI/ADYNOVATE
- Where
- 36 sites in United States, Bulgaria and 11 more
- Volunteers
- 207 people
- Sponsor
- Baxalta now part of Shire
Hemophilia A
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
This multicenter, open-label study will evaluate the safety, efficacy and pharmacokinetics of prophylactic emicizumab treatment in participants previously treated with episodic or prophylactic bypassing agents.
- Trial name
- HAVEN 1 (NCT02622321)
- Testing
- Emicizumab, rFVIIa, aPCC
- Where
- 44 sites in United States, Australia and 12 more
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
Advanced MDS, Acute Myeloid Leukemia
A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia
This is a 2-phase study during which patients with select myeloid leukemias or advanced myelodysplastic syndrome (MDS), who have failed, refused or are not eligible for standard treatment, will receive investigational study drug…
- Trial name
- NCT00637052
- Testing
- ARRY-520, KSP(Eg5) inhibitor; intravenous
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pfizer
Leukemia
A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies
The primary objective is to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD), or pharmacological active dose (PAD) of BAY2402234 in patients with acute myeloid leukemia (AML), myelodysplastic…
- Trial name
- NCT03404726
- Testing
- BAY2402234
- Where
- 5 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Bayer
Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as…
- Conditions
- Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes
- Trial name
- NCT04891757
- Testing
- FHD-286, Low Dose Cytarabine, Decitabine
- Where
- 5 sites in United States
- Volunteers
- 144 people
- Sponsor
- Foghorn Therapeutics Inc.
Prophylaxis Of Invasive Fungal Infections
Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants
- Trial name
- VOSIFI (NCT00143312)
- Testing
- voriconazole
- Where
- 17 sites in Belgium, France and 6 more
- Volunteers
- 45 people
- Sponsor
- Pfizer
HTLV-I Infections, HTLV-II Infections
MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study
This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50).
- Conditions
- HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2
- Trial name
- NCT03226119
- Testing
- MP Diagnostics HTLV Blot 2.4
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- MP Biomedicals, LLC
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis, Postessential Thrombocythemia (Post-ET) Myelofibrosis
- Trial name
- NCT02515630
- Testing
- MMB
- Where
- 13 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Multiple Myeloma
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of siltuximab in participants with relapsed (the return of a disease or the signs and symptoms of a disease after a period of improvement.) or refractory (cancer…
- Trial name
- NCT00402181
- Testing
- Siltuximab, Dexamethasone
- Where
- 13 sites in United States, Netherlands
- Volunteers
- 53 people
- Sponsor
- Centocor, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.